Frank Nygaard is a seasoned CMC Director specializing in Drug Substance Development, with extensive experience in both early and late-phase R&D and technology transfer within the biotech industry. They have held leadership roles at several organizations, including Nykode Therapeutics and Symphogen, overseeing critical processes in drug development and manufacturing. Frank has a Ph.D. in Biochemistry and an M.Sc. from the University of Copenhagen, demonstrating a strong foundation in protein chemistry and biopharmaceuticals. Their expertise encompasses product and process understanding, feasibility studies, and business development, with a focus on advancing innovative therapeutic solutions globally.
This person is not in any teams
This person is not in any offices